Sign in →

Order Code LABTBBS Quantitative Lymphocyte Subsets: T, B, and Natural Killer (NK) Cells, Blood

Important Note

CD4 AND CD8 QUANTITATION BY FLOW CYTOMETRY

Additional Codes

Mayo Test ID
TBBS

Reporting Name

QN Lymphocyte Subsets: T, B, and NK
Ridgeview Laboratory Note:

  **It is recommended that specimens arrive within 24 hours of draw. Draw and package specimen as close to shipping time as possible.
Purple top EDTA in original tube

Useful For

Serial monitoring of CD4 T-cell count in patients who are HIV-positive

 

Follow-up and diagnostic evaluation of primary immunodeficiencies, including severe combined immunodeficiency

 

Immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized

 

Assessment of immune reconstitution post-hematopoietic cell transplantation

 

Early screening of gross quantitative anomalies in lymphocyte subsets in infection or malignancies

 

Absolute quantitation of circulating B cells for diagnosis of patients with chronic lymphocytic leukemia as indicated in the 2008 International Workshop on Chronic Lymphocytic Leukemia guidelines

Specimen Type

Whole Blood EDTA


Ordering Guidance


This assay should not be used for diagnosing lymphocytic malignancies or evaluation of lymphocytosis of unknown etiology. For such cases, order LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies, which includes a hematopathology review.

 

This assay can be used for absolute quantitation of B cells in patients with chronic lymphocytic leukemia.

 

While this assay can be used to follow patients on B-cell-depleting therapy, like rituximab (eg, Rituxan, Riabni) or ofatumumab (eg, Kesimpta), it may be more reasonable and financially viable to use CD20B / CD20 on B Cells, Blood (includes CD45, CD19 and CD20 markers).



Shipping Instructions


It is recommended that specimens arrive within 24 hours of collection. Collect and package specimen as close to shipping time as possible.



Necessary Information


Date and time of collection are required.



Specimen Required


Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.

Additional Information: For serial monitoring, it is recommended that specimen collection be performed at the same time of day.


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole Blood EDTA Ambient 52 hours PURPLE OR PINK TOP/EDTA

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject

Reference Values

The appropriate age-related reference values will be provided on the report.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Day(s) Performed

Monday through Sunday

Method Name

Flow Cytometry

CPT Code Information

86355

86357

86359

86360

Method Description

The T-, B-, and natural killer (NK)-cell surface marker assay uses monoclonal antibodies to identify the various membrane antigens, and flow cytometry to enumerate the number of cells expressing these differentiation antigens. CD14 is used to exclude monocytes, thereby improving accuracy and enhancing the purity of the lymphocyte population. The results are reported as the percent of lymphocytes that are total T cells (CD3+), CD3+CD4+ T cells, CD3+CD8+ T cells, natural killer (CD16+56+, CD3-), and B-lymphocytes (CD19+), and the absolute number of each cell type per mL of blood. The assay is a 7-color no-wash procedure, and the absolute counts are calculated from internal bead standards. In addition, the total lymphocyte count and CD4:CD8 ratio are reported.(Hoffman RA, Kung PC, Hansen WP, Goedstien G. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA. 1980:77(8):4914-4917; Mandy FF, Nicholson JK, McDougal JS; CDC. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-2):1-13)